🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Pleased to see our meta-analysis published Hira Mian Bram Rochwerg #MYELOMA Maintenance therapy in transplant ineligible adults with newly‐diagnosed multiple myeloma: a systematic review and meta‐analysis onlinelibrary.wiley.com/doi/abs/10.111…

Catching up on yesterday’s talks - ⁦Hira Mian⁩ highlighting symptom burden in transplant ineligible MM. great job Hira! #ASH2020 #MYELOMA #gerionc

Israel: 11.55% vaccinated. Canada: 0.29%.

Excited to attend this event! Hoping to see my Hamilton Health Sciences PHRI.ca Population Health Research Institute 🇨🇦 colleagues Menaka Pai, MSc MD FRCPC Madeleine Verhovsek, MD FRCPC Amaris Balitsky Joanna Dionne Dina khalaf

External validation of Facons simplified frailty scale was associated with decreased OS, and increased EM and HCU among NDMM patients in our population cohort with Hsien Seow PhD Greg Pond Amaris Balitsky Smit Giri MD MHS @tanyawildes @ArleighMccurdy Myeloma Canada nature.com/articles/s4137…

Our latest, 12820 PRO assessments captured among nearly 2000 MM pts in Ontario, Canada showing the trajectory of symptoms following ASCT with ICES Greg Pond Myeloma Canada Hsien Seow PhD Amaris Balitsky @tanyawildes doi.org/10.1016/j.clml…

Use of PROMs in predicting ED and hosp visits in older adults with TIE MM in a population based cohort. Our ash abstract out in print now. doi.org/10.1038/s41408… Blood Cancer Journal with Amaris Balitsky @adsouza_md @tanyawildes Hsien Seow PhD Greg Pond Myeloma Canada

Check out our review paper: Important questions for the malignant hematologist to consider when designing or evaluating a study with patient‐reported outcome measures (PROMs) @adsouza_md onlinelibrary.wiley.com/doi/10.1111/ej…

An important book for those in the field. Thank you ⁦Vinay Prasad MD MPH⁩

A balanced perspective on the use/role of brentuximab in advanced HL Gwynivere Davies A Better Treatment for Advanced-Stage Hodgkin’s Lymphoma? | NEJM nejm.org/doi/full/10.10…

Number 3!!! Can we please adopt this Hamilton Health Sciences. Unnecessary extra blood draws and delays for our patients.

Incredible person, colleague and above all leader! With Chris Hillis Amaris Balitsky Gwynivere Davies McMaster University Department of Medicine

⁦superstar colleague ⁦Hira Mian⁩ presenting ASH highlights in a 🇨🇦 context #ASH2022, #CAREatASH

How should we treat late (and early) CAR-T failures? Novel targeted drugs and bispecifics, this is not the population for CT or tafa/len as supported by multiple other abstracts. Erbella, ASH #553. #ASH22

There is a blood product shortage. I booked my appointment! Dr. Tom Kouroukis Chris Hillis Gwynivere Davies Hira Mian Siraj Mithoowani Menaka Pai, MSc MD FRCPC Joanne Britto Mike Radford Madeleine Verhovsek, MD FRCPC Michelle Zeller Donald M. Arnold myaccount.blood.ca/en/donate/veri…

Elsevier is losing editors

Raising funds to support the highest priority needs of the Cancer Program at Juravinski Hospital and Cancer Centre Juravinski Lymph Nodes - Illuminight 2024 (akaraisin.com)

Just published systematic review- monitoring oncology patients’ status by asking them to complete patient-reported outcome measurements reduces mortality and improves quality of life. Gordon H. Guyatt Hira Mian Joanne Britto pubmed.ncbi.nlm.nih.gov/39136947/

Bispecific antibody toxicities: Two unique toxicities of bispecific antibodies are cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome. ➡️ cmaj.ca/lookup/doi/10.… (earn CPD credits) Joanne Britto Gwynivere Davies Amaris Balitsky Hira Mian